Casitas B-lineage lymphoma (CBL) protein family functions as multifunctional adaptor proteins and E3 ubiquitin ligases that are implicated as regulators of signaling in various cell types. Recent discovery revealed mutations of proto-oncogenic CBL in the linker region and RING finger domain in human acute myeloid neoplasm, and these transforming mutations induced carcinogenesis. However, the adaptor function of CBL mediated signaling pathway during tumorigenesis has not been well characterized. Here, we show that CBL is highly expressed in breast cancer cells and significantly inhibits transforming growth factor-b (TGF-b) tumor suppressive activity. Knockdown of CBL expression resulted in the increased expression of TGF-b target genes, PAI-I and CDK inhibitors such as p15
INTRODUCTION
Transforming growth factor-b (TGF-b) is a multifunctional cytokine that mediates diverse biological processes, such as differentiation, cell cycle, apoptosis and pathogenesis. 1 --3 The TGF-b signaling pathway has a complex role during tumor progression. 2 During the earlier stages of tumorigenesis, TGF-b functions predominantly as a tumor suppressor protein that inhibits growth of transformed cells. But later in tumor development, when carcinoma cells become refractory to TGF-b-mediated growth inhibition, TGF-b signaling pathway in the tumor microenvironment enhances tumor progression.
Human cancer cells frequently demonstrate resistance to the normal growth-inhibitory effects of TGF-b. 4, 5 Mutations and transcriptional repression of the TGF-b receptor type II (TbRII) have been described in human tumors. 4, 6 Decreased expression of Smad3 and Smad4 or loss-of-function mutations in at least one of these genes has been observed in advanced stages of certain cancers. 7 In addition, cellular proteins such as ETV6-NTRK3 chimeric oncoprotein and TrkC receptor tyrosine kinase are known to suppress TGF-b -tumor suppressor activity through the interaction with TbRII and inhibition of TbRI --TbRII complex formation. 8, 9 Casitas B-lineage lymphoma (CBL) gene encodes for the proteins involved in many cellular processes such as E3 ubiquitin ligase and adaptor. 10, 11 Among three homologs of the CBL protein family, CBL (also known as c-CBL) and CBL-b are ubiquitously expressed and have similar functions. 12 They commonly contain tyrosine-kinase-binding domain and a RING finger type (RF) domain that has E3 ubiquitin ligase activity. They have been reported to have a role as a negative regulator of receptor tyrosine kinase, including epidermal growth factor receptor, by inducing endocytosis and lysosomal degradation through ubiquitination. 10 Therefore, CBL is normally regarded as a negative regulator of proliferation. CBL affects cancer development. In myeloid neoplasm and lung cancer, mutations of CBL can induce cancer, 13 --17 and in prostate cancer, the wild-type CBL enhances tumor formation. 18 CBL also functions as an adaptor protein in the signal transduction. CBL and CBL-b contain multiple protein interaction motifs such as the proline-rich regions that bind to SH3 domains of numerous signal-transducing molecules; and tyrosine residues that become phosphorylated and interact with the key SH2 domain-containing signaling proteins. Although a number of proteins interacting with CBL have been identified, the functional significance of these protein --protein interactions is largely unknown.
Here, we show that CBL suppresses TGF-b signaling by directly binding to Smad3, a key component of TGF-b signaling, thereby preventing it from forming a complex with Smad4 and activating downstream TGF-b effector cascades. CBL also inhibits nuclear translocation of Smad3 protein upon TGF-b stimulation. Interestingly, CBL is overexpressed in a number of primary human breast cancer tissue samples, indicating that CBL may have oncogenic activity through inhibiting the tumor suppressive activity of TGF-b signaling.
RESULTS

CBL inhibits TGF-b signaling in breast cancer cell
To identify novel modulating cellular proteins of TGF-b signaling, a yeast two-hybrid screen was performed by using the human brain cDNA library with either cytoplasmic domain of TbRII or Smad3 separately as a bait. From an estimate of 1.0 million transformants, ten clones were selected being positive (data not shown). Sequence analysis showed that one of these clones encoded CBL. We searched the Oncomine on-line database (http:// www.oncomine.org) to investigate how CBL affects TGF-b signaling in cancer and found relatively high expression of CBL in breast cancer among various cancer types. We conducted an immunoblotting analysis to compare the expression level of CBL in eight human breast cancer cell lines against an immortalized human breast cell line, MCF10A1. The result clearly indicated an overexpression of CBL in majority of the breast cancer cell lines (Figure 1a) . Among the breast cancer cell lines examined, we selected Hs578T and MDA-MB231 cell lines for the further study.
To test whether CBL influences TGF-b1-induced transcriptional activation, we transfected a control or CBL expression vector together with the TGF-b1-responsive SBE4-Luc reporter construct, which contains four SBE sites in tandem or the CAGA 12 -Luc reporter construct, into Hs578T. The expression of CBL significantly repressed the TGF-b1-dependent activities of these reporter gene constructs (Figure 1b) . To see if the loss of CBL reverses this effect, we made CBL knockdown-stable Hs578T cell line using small interfering RNA (siRNA) lenti-viral system and carried out TGF-b1-induced transcription reporter assay. We observed that the downregulation of CBL enhances TGF-b1-induced transcriptional activity (Figure 1c ). Subsequently, we investigated whether CBL knockdown also influences TGF-b1-mediated cell growth inhibition in Hs578T cell line. In comparison with control-siRNA cells, knockdown of CBL expression enhanced the ability of TGF-b1 to inhibit proliferation (Figure 1d ). These results suggest that CBL suppresses TGF-b1-mediated transcriptional activation and cell growth inhibition in human breast cancer cell line.
CBL knockdown enhances TGF-b1 target gene expression TGF-b1-mediated cell growth inhibition occurs through upregulation of cell cycle arrest-related genes including CDKN2B and CDKN1A (which encode p15
INK4b and p21
Cip1
, respectively). 3 We examined whether knockdown of CBL expression enhances endogenous TGF-b1-responsive genes known to be involved in cytostatic actions (SERPINE1(PAI-I), CDKN2B and CDKN1A) by quantitative PCR and western blot analysis using Hs578T and MDA-MB231 cell lines carrying CBL-siRNAs. In comparison with the control cells, knockdown of CBL expression further induced transcription of these genes in response to TGF-b1 in both cell lines (MDA-MB231 has CDKN2B locus deletion 19 ; Figure 2a ). Congruently, the levels of PAI-I, p15
INK4b and p21 Cip1 proteins were also increased in both cell lines carrying CBL-siRNAs in response to TGF-b1 treatment (Figure 2b ). Taken together, these data indicate that CBL suppresses TGF-b1 signaling and overexpression of CBL may lead to the inactivation of TGF-b1 growth inhibitory activity as well as transcriptional activity in human breast cancer cells.
Loss of CBL reduced tumor formation of breast cancer cell line in vivo, and CBL is expressed highly in primary human breast cancer tissues We tested the effect of CBL on tumorigenicity of breast cancer cells in vivo using xenograft assay. MDA-MB231 cells expressing CBL-siRNA formed smaller tumors in athymic nude mice compared with the control (Figures 3a --c) . In tumor tissues, knockdown of CBL was confirmed by using reverse transcription (RT)--PCR (Figure 3d ). We suggest that decreased CBL expression may reduce growth of breast cancer xenografts through enhancing TGF-b tumor suppressive activity.
We examined CBL expression in thirty invasive human breast tumors by RT--PCR (only eight shown, Figure 3e ) and immunostaining to determine whether expression of CBL correlates with certain pathological phenotypes in clinical breast tumor samples. Approximately 50% of primary human breast cancer showed elevated CBL expression compared with normal breast tissue samples (Figure 3e ). CBL expression was also checked by immunohistochemistry. Representative result (case no. 4) is shown in Figure 3f where the immunoreactivity of CBL was observed only in tumor region. CBL was extensively expressed in the cytoplasm, suggesting that such aberration may contribute to the pathogenesis of human invasive breast carcinomas.
CBL interacts with Smad3, a core component of TGF-b signal pathway To study the mechanism behind the suppression of TGF-b signal by CBL, we tested the interaction of either TbRII or Smad3 with human CBL protein in mammalian system using transiently transfected 293T cells with a plasmid encoding either Flag-tagged TbRII or GFP-tagged Smad3 together with Myc-tagged CBL. CBL specifically interacted with Smad3, but not with type II TGF-b receptor (Figure 4a and Supplementary Figure 1) . To examine whether CBL also interacts with Smad2 and Smad4, Myc-CBL was expressed in 293T cells with GFP-Smad2, GFP-Smad3, or GFPSmad4 and coimmunoprecipitation assays were performed. CBL showed a strong binding affinity to Smad3, whereas only a weak interaction with Smad2, but did not bind to Smad4 ( Figure 4a ). Next, we examined whether Smad3 phosphorylation by TbRI kinase is required for Smad3/CBL interaction by the use of a constitutively active form of TbRI (T204D, TbRI ca). As anticipated, TbRI ca phosphorylated Smad3 and enhanced the interaction between Smad3 and CBL (Figure 4b ), suggesting that TGF-b signaling triggers the association between CBL and Smad3. To confirm this result, we examined the ability of an inactive form of Smad3 mutant (AAVA, serine amino acids replaced with alanine) or a constitutively active Smad3-like mutant (DDVD, serine amino acids replaced with aspartic acid) in C-terminal SSXS motif of Smad3 20, 21 to interact with CBL. CBL/Smad3 interaction was mostly abrogated by the inactive form of Smad3 AAVA mutant, but greatly enhanced by Smad3 DDVD mutant (Figure 4c ). These results suggest that TbRI kinase has a key role in the regulation of CBL and Smad3 interaction.
To test whether CBL interacts with Smad3 in vivo upon TGF-b stimulation, Hs578T cells were treated with TGF-b1 for up to 60 min and coimmunoprecipitation assays were performed. Endogenous CBL and Smad3 co-precipitated together, but only in TGF-b1-treated cells showed the most abundant association (at 30 min; Figure 4d ), suggesting that TGF-b1 specifically triggers the association between CBL and Smad3.
We next attempted to determine which region of CBL is responsible for the interaction with Smad3. We generated various deletion mutants lacking the E3 ligase region or the proline-rich region of CBL. Smad3 was only able to bind to CBL mutants with proline-rich region of CBL (Figure 4e ). These results indicate that the proline-rich region of CBL encompasses a site responsible for the interaction with Smad3. Correspondingly, MH2 domain of Smad3 was shown to be important for interaction with CBL ( Figure 4f ). Thus, CBL binds to MH2 domain of Smad3 through its proline-rich domain.
Homozygous CBL mutants have been identified in myeloid malignancies. 13 --16 CBL mutants (CBL Q367P and CBL Y371S), as well as a mouse lymphoma-derived oncogenic mutant (CBL 70Z) are known to be involved in the pathogenesis of myeloid neoplasms.
14 These transforming mutations all have deletion or mutations within the linker region and RF, and have lost E3 ligase activity. We examined the ability of these mutants to bind Smad3. All of these mutants were able to interact with Smad3 in a similar extent to wild-type CBL (Figure 4g ), suggesting that the linker region and RF of CBL are not involved in the association between CBL and Smad3.
CBL interferes with Smad3/4 complex formation through binding to Smad3 As neither the knockdown nor the exogenous expression of CBL wild type and mutants showed any effect on the Smad2/3 phosphorylation ( Supplementary Figures 2a and b) , we hypothesized that CBL suppresses the cellular responses of TGF-b by disrupting the Smad3/4 complex formation, a downstream of Smad phosphorylation in TGF-b1 signaling cascade. To elucidate the underlying mechanism by which the association between CBL and Smad3 interferes the TGF-b/Smad signaling, we tested how overexpression of CBL affects the Smad3/4 complex formation by To investigate the importance of CBL --Smad3 interaction in the suppression of TGF-b signaling, we examined a change in TGF-b1-induced transcriptional activity by the CBL wild type and deletion mutants. Only the wild type and a deletion mutant (D4) of CBL, both containing a Smad3 binding region, retained the suppressive activity (Figure 5c ). Contrastingly, D1 mutant with a RING-type domain did not bind to Smad3, thus it showed no suppressive effect. These results suggested that the crucial mediating factor in suppression of TGF-b signaling by CBL is its ability to bind to Smad3.
We also assessed the effects of transforming mutant forms of CBL on TGF-b1-induced transcriptional activity by co-transfection of the CBL expression plasmid and the SBE4-Luc to show whether E3 ubiquitinase activity of CBL affects TGF-b signaling. Wild-type CBL as well as CBL mutants, CBL (Y371S) and CBL (70Z), suppressed TGF-b1-induced transcriptional activity (Figure 5d ), suggesting that E3 ligase is not involved in CBL-mediated suppression of TGF-b1-induced transcriptional activity.
CBL blocks Smad3 nuclear translocation TGF-b-induced transcriptional regulation is controlled by nuclear translocation of Smad3. Therefore, to determine whether CBL has an effect on the subcellular localization of Smad3, we transfected the Myc-CBL expression construct into Hs578T cells and performed confocal microscopic analysis using anti-Myc and anti-Smad3 antibodies. Most CBL localized to the cytoplasm regardless of TGF-b1 treatment, whereas endogenous Smad3 was found in both nuclear and cytoplasmic compartments. Colocalization of Smad3 and CBL was observed in the perinuclear region even without TGF-b1 treatment. After TGF-b1 treatment, majority of Smad3 translocated to the nucleus, but in a cell expressing Myc-CBL, nuclear translocation of Smad3 was significantly blocked and accumulation of both CBL and Smad3 in the perinuclear region was markedly increased (Figure 6 and Supplementary Figure 3) , which suggest that activated Smad3 may preferentially bind to CBL. This obstruction of Smad3 nuclear translocation by CBL may contribute to suppressive effect of CBL on Smad3-dependent transcriptional activity.
Knockdown of both CBL and CBL-b further enhances TGF-b transcriptional activity Among the CBL family proteins, CBL and CBL-b have been reported to have similar structure and function. 12 We found that CBL-b also interacts with Smad3 (Figure 7a ). Therefore, we investigated whether CBL-b has a similar effect as CBL on TGF-b signaling in human breast cancer. We used siRNA technology to knockdown CBL-b alone or both CBL and CBL-b in Hs578T cells. Expression of siRNAs specific to either CBL or CBL-b effectively reduced the endogenous CBL and CBL-b levels as compared with control cells (Figure 7b) . We examined the expression of endogenous TGF-b1-responsive genes, PAI-I and CDKN2B, by quantitative PCR and western blot analysis. In comparison with control, knockdown of either CBL or CBL-b expression improved transcription of these genes in response to TGF-b1, in addition to knockdown of both CBL and CBL-b synergistically enhanced the transcription of these genes significantly and also enhanced the interaction between endogenous Smad3 and 4 ( Figure 7c and Supplementary Figure 4) . Accordingly, the levels of p15
INK4b proteins were further increased in Hs578T cell lines carrying both CBL-siRNAs and CBL-b-siRNAs in response to TGF-b1 treatment (Figure 7d ).
DISCUSSION
The identification of recurrent transforming CBL mutations in patients with myeloid neoplasms and lung cancers has clearly established that CBL is an important factor in carcinogenic progression. The majority of the mutations found in human myeloid neoplasms occurs within the linker region or RF domain that is central to the E3 ubiquitin ligase activity. A recent report demonstrated that CBL mutants, which have lost E3 ligase activity, acts as an oncogene leading to prolonged tyrosine kinase activation after ligand stimulation.
14 Although the nature of CBLinteracting proteins in distinct cellular compartments is well established, the functional importance of these protein --protein interactions is poorly understood. In this report, we show that the CBL suppresses TGF-b signaling by disrupting the Smad pathway. CBL specifically interacts with Smad3 and blocks its ability to activate downstream signaling, including binding to Smad4 and Smad3 nuclear translocation after TGF-b1 stimulation. Our results introduce a novel mechanism for inhibition of TGF-b1-mediated growth suppression in human breast cancer cells. These findings provide evidences for a unique role of CBL as a negative regulator of TGF-b tumor suppressive pathway.
TGF-b signal transduction regulates pathogenesis as well as other various cellular processes. Abrogation of TGF-b signaling raises the risk of inflammation and cancer development. The abnormal regulation in TGF-b signaling arises from genetic defect and/or epigenetic changes. 2 When negative regulators of TGF-b signal pathway are epigenetically overexpressed, normal cells can transform into cancer cells. In breast cancer, several E3 ligases such as WWP1, b-Trcp1 and CHIP 22 --24 have been reported as negative regulators of the TGF-b signal pathway through ubiquitination and degradation of core components of TGF-b signaling. However, in our study, CBL does not require its E3 ligase activity for modulating TGF-b signaling. Instead, CBL may have a role as an adaptor protein, which interacts with Smad3 for regulation of TGF-b signal pathway.
Smad3 binds to Smad anchor for receptor activation (SARA), Smad4 or nucleoporins for TGF-b signal transduction through its MH2 domain. 25 --28 SARA enhances binding affinity of Smad3 to activated TbRs by interacting with Samd3 and this interaction is weakened when Smad3 is phosphorylated. Smad3 dissociated from SARA form a complex with Smad4, translocate into the nucleus and then activate TGF-b target genes. 25 Smad3 itself can translocate into the nucleus by binding to nucleoporins (such as CAN/Nup214 and Nup153) through its MH2 domain. 27 Herein, we show that CBL binds to the MH2 domain of Smad3 and competes with Smad4 for forming a complex with Smad3. When Smad3 is activated in exogenous CBL-expressed cells, it shows reduced nuclear translocation due to stronger interaction with CBL ( Figures  4, 5 and 6 ). Consequently, we suggest that CBL decreases TGF-b1-induced transcriptional activity by competing with Smad4 and nucleoporins for binding to Smad3, which results in blocking nuclear translocation of Smad3. Mutation of CBL gene induces carcinogenesis. E3 ligase inactive mutations of CBL, such as Q367P and Y371S, which were discovered in myeloid neoplasm, make normal fibroblast cell lines to form tumor in mouse dorsal subcutaneous spaces.
14 Oncogenic mutants of CBL have been investigated on how they induce carcinogenesis. One of the carcinogenic mechanisms of CBL mutants is the inability to ubiquitinate and degrade cell-growthrelated RTKs due to inactivated E3 ligase functions. This loss of function prolongs the life span of RTK proteins and enhanced growth factor signal transduction, such as PI3K/AKT and STAT signaling.
14 CBL mutants detected in lung cancer that were outside of the linker and RF domains have intact E3 ligase activity, but enhance viability of lung cancer cells. This finding suggested the E3-independent functions of CBL in the pathogenesis of human cancers. Our findings here suggest that the oncogenic effect of CBL mutants is probably the combination of the activation of PI3K/AKT and STAT signaling, as well as suppression of TGF-b tumor suppressor activity by CBL. Our hypothesis is supported by a recent publication that demonstrated CBL as a novel basal cell marker in human prostate cancer. CBL is overexpressed in human prostate cancer tissues and increased protein level of CBL was associated with decreased patient survival. 18 Taken together with our finding that CBL is frequently overexpressed in the human breast cancers, it is likely that increased expression of CBL may also be oncogenic. The fact that knockdown of CBL in PC3 prostate cancer cells decreased proliferation is very interesting. 18 It raises an interesting question of whether CBL also functions as a negative regulator of TGF-b signaling in PC3 cells. CBL exerts its functions either through E3 ligase activity or as an adaptor to recruit other molecules. CBL as E3 ligase for a number of receptor/protein tyrosine kinases is relatively well characterized, however, CBL as an adaptor in signal transduction is not well known. CBL and CBL-b contain multiple protein interaction motifs such as the proline-rich regions that bind to SH3 domains of various signaling proteins. The carboxylterminal of CBL interacts with various SH2 and SH3 domaincontaining proteins.
11 Given CBL's role as an adaptor of various signaling molecules, it is significant that we identified Smad3 as a CBL-interacting protein to suppress TGF-b tumor suppressor pathway.
In conclusion, we have identified that the CBL suppresses TGF-b signaling. CBL specifically interacts with Smad3, thereby leading to the inhibition of Smad3 --Smad4 complex formation and Smad3 nuclear translocation. This provides a unique role of CBL as an adaptor for Smad3 in human breast cancers.
MATERIALS AND METHODS
Expression plasmids, antibodies and chemical CBL cDNA for human was cloned by the RT--PCR method. All of CBL and Smad3 mutants were made by either site-directed or the PCRdeletion mutagenesis method. 29 CBL and its mutants were inserted into pCMV-Myc vector (Clontech, Mountain View, CA, USA). GFP-Smad2, 3 and 4 were constructed by introduction of Smad2, 3 and 4 into pEGFP-C2. Flag-Smad3 domain constructs and constitutively active HA-TbRI ca plasmids constructs were described previously. 21, 30 Anti-Myc, HA, CBL, CBL-b, GFP, p15
INK4b p21 Cip1 and PAI-I antibodies were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA. Anti-atubulin and Flag M2 antibody was from Sigma-Aldrich, St Louis, MO, USA. Anti-phospho-Smad3 and Smad3 (ab28379) antibodies were obtained from Abcam, Cambridge, MA, USA. Anti-phospho-Smad2 and Smad2 antibodies were from Cell signaling, Inc., Danvers, MA, USA. Human recombinant TGF-b1 was purchased from R&D Systems, Minneapolis, MN, USA.
Cell culture and transfection
Cell lines used in this study were purchased from the American Type Culture Collection (Manassas, VA, USA) and the culture conditions were maintained according to their guideline. Cells were transfected with FuGENE6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA).
Transcription reporter assay SBE4-Luc and CAGA 12 -Luc plasmids were used for TGF-b1-induced transcription reporter assay. pCMV-b-gal was co-transfected to normalize transfection efficiency. At 24 h hour post transfection, cells were treated with 5 ng/ml TGF-b1 for 24 h. For luciferase analysis, cells were harvested with Luciferase Cell Culture Lysis reagent (Promega, Madison, WI, USA). Luciferase activities were measured using the Luciferase Assay System (Promega) according to the manufacturer's protocol. The absorbance at 470 nm was measured using SpectraMax L luminescence microplate reader (Molecular Devices, Sunnyvale, CA, USA). b-Galactosidase activities were assessed using o-nitrophenyl-b-D-galactoside and 1 M Na 2 CO 3 . All values were normalized with b-galactosidase activities.
RNA interference
The CBL target siRNA lenti-viral vectors (based on pLKO-puro.1 vector) were purchased from Sigma-Aldrich. The CBL-b target siRNA sequences (ACAGACCCTTTGTAGCGTG, at position 3648 to 3666) were obtained from Dharmacon siDesign Center program (Thermo Fisher Scientific, Waltham, MA, USA). Synthetic sense and antisense DNA oligonucleotides were annealed and cloned into pLKO-puro.1 vector. As a siRNA control, pLKOpuro.1, which contains a GL2 luciferase target sequence (CGTACGCGGAA TACTTCGA), was used. Forty-eight hours post transfection of siRNA constructs into 293T, medium containing the viruses were harvested. siRNA expressing stable Hs578T and MDA-MB231 cell lines were generated by viral infection and selected with 2.5 or 1 mg/ml of puromycin.
Cell proliferation assay A total of 2 Â 10 3 cells per well were seeded in 96-well plates with cell culture medium supplemented with 0.5% and penicillin/streptomycin, and incubated for overnight before TGF-b1 treatment. Cell proliferation was checked for 3 days after TGF-b1 treatment using CellTiter-Glo Luminescent Cell Viability Assay Reagent (Promega). The absorbance at 470 nm was measured using SpectraMax L luminescence microplate reader (Molecular Devices).
Immunoprecipitation and western blot analysis
Transfected or untransfected cells were washed with phosphate buffered saline and lysed in lysis buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 10% Glycerol, 5 mM EDTA, 1% Triton X-100 and a complete protease inhibitor cocktail (Roche). Epitope-tagged or endogenous proteins in cell lysates were incubated with the appropriate primary antibodies overnight at 4 1C. Antibody-bound proteins were precipitated with Dynabeads Protein G (Invitrogen, Carlsbad, CA, USA) according to the protocol provided by the manufacturer. After the beads were washed for four times with 500 ml lysis buffer, they were eluted in SDS sample loading buffer. Eluted proteins were separated by SDS --polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membrane (Millipore, Billerrica, MA, USA), and detected with appropriate primary antibodies coupled with horseradish peroxidase-conjugated secondary antibody by chemiluminescence (GE healthcare Life Sciences, Piscataway, NJ, USA).
Immunofluorescence
Cells seeded on chamber slides were fixed with ice-cold acetone for 5 min on ice. Cells were blocked with 5% BSA for 1 h and stained with Myc or Smad3 antibody overnight at 4 1C. Antibody-bound cells were detected by Alexa Fluor 488 or 594-conjugated secondary antibody (Invitrogen). Immunofluorescence images were obtained with a Zeiss LSM META 510 confocal microscope (Carl Zeiss, Sachsen, Thü ringen, Germany).
Clinical materials
Human tissue samples were obtained from female patients with invasive primary breast cancer at Gangnam Severance Hospital. The study was approved by the Institutional Review Board.
Immunohistochemistry
Paraffin-embedded human breast tissue sections were immunostained as described previously. 31, 32 Xenograft assay Six-week-old female athymic nude mice used for the in vivo experiments were maintained in accordance with the standards of the Institutional Animal Care and Use Committee. A total of 2.5 Â 10 6 cells were injected into subcutaneous area of mice with matrigel (BD sciences, San Jose, CA, USA). Tumor sizes were measured using a vernier caliper weekly and calculated using the formula (sagittal dimension (mm) Â (cross dimension (mm)) 2 /2. Mice were killed 4 weeks after xenograft and tumors were harvested for additional analysis.
Reverse transcription and semi-or quantitative PCR Total RNA was isolated from tissues and cells using TRIzol reagent (Invitrogen) following manufacturer's protocol. Reverse transcription was carried out with 1 mg of pure RNA using SuperScriptTM II reverse transcriptase (Invitrogen). Synthesized cDNA was amplified by PCR using specific primers. Semi-quantitative PCR was carried out and PCR products were visualized by electrophoresis on agarose gels with ethidium bromide staining and analyzed with ImageQuant LAS 4000 image analyzer (GE Healthcare Life Sciences). 18S rRNA and GAPDH served as the housekeeping genes. Quantitative PCR was performed using Assay-onDemand kits and Viia 7 real-time PCR device (Applied Biosystems, Carlsbad, CA, USA).
Yeast two-hybrid screening
Screening with the full length of human TbRII or Smad3 as bait for finding binding partner was performed using the Matchmaker Yeast Two-hybrid System 3 (Clontech). The pGBK-T7-TbRII or Smad3 was cloned and transformed into the AH109 yeast strain using the lithium acetate method. Expression of TbRII or Smad3 proteins was examined by immunoblotting. The AH109 strain expressing TbRII or Smad3 was mated with pre-transformed Y187 containing the human brain cDNA library and selected onto adenine --histidine --tryptophan---leucine-deficient selective plates. The library DNA was extracted from the selected yeast strain and sequenced using the Big Dye terminator method (Applied Biosystems).
Statistical analysis
All quantitative data were expressed as the mean ± s.d. Statistical analysis was performed with one-way analysis of variance using SPSS software (IBM, Armonk, NY, USA). A value of Po0.05 was considered statistically significant.
